Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeCost of RevenueEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Equity IncomeGross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesPreferred Dividend PaymentsProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)Tax ProvisionsTax Rate
Others
Ratios

Ani Pharmaceuticals (ANIP) Tax Provisions (2016 - 2025)

Historic Tax Provisions for Ani Pharmaceuticals (ANIP) over the last 14 years, with Q3 2025 value amounting to $7.2 million.

  • Ani Pharmaceuticals' Tax Provisions rose 19819.97% to $7.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $10.0 million, marking a year-over-year increase of 253203.88%. This contributed to the annual value of -$3.7 million for FY2024, which is 43760.29% down from last year.
  • According to the latest figures from Q3 2025, Ani Pharmaceuticals' Tax Provisions is $7.2 million, which was up 19819.97% from $2.0 million recorded in Q2 2025.
  • In the past 5 years, Ani Pharmaceuticals' Tax Provisions ranged from a high of $7.2 million in Q3 2025 and a low of -$7.3 million during Q3 2024
  • Its 5-year average for Tax Provisions is -$962722.2, with a median of -$1.2 million in 2022.
  • In the last 5 years, Ani Pharmaceuticals' Tax Provisions crashed by 5790000.0% in 2022 and then surged by 88181.82% in 2024.
  • Quarter analysis of 5 years shows Ani Pharmaceuticals' Tax Provisions stood at -$6.7 million in 2021, then skyrocketed by 78.13% to -$1.5 million in 2022, then soared by 85.84% to -$208000.0 in 2023, then plummeted by 1575.96% to -$3.5 million in 2024, then surged by 306.54% to $7.2 million in 2025.
  • Its Tax Provisions was $7.2 million in Q3 2025, compared to $2.0 million in Q2 2025 and $4.3 million in Q1 2025.